In this regard, dysregulated immune systems coupled with cytokine storms, mainly involving overproduction of interleukin-6 (IL-6), are important causes of death in severe COVID-19 [48]; thus, tocilizumab and sarilumab, acting as antagonists of the IL-6 receptor, have been proposed for the management of critically ill patients [37, 47]. The gene discussed is IL6; the disease is COVID-19.